Skip to main content
LSTA logo

LSTA · Lisata Therapeutics, Inc.

Track LSTA — free
$1.68 -0.22 (-11.58%)
Market Cap
$17.12M
Shares
9.01M

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.90 Open$1.86 Day$1.73–2.00 52W close$0.99–5.04 Avg vol 30d397K Short int90K · 1.0% float · 1.1d Short vol16% Last earningsNov 6, 2025 DataSep 2022–Sep 2026 Filing10-Q · Aug 6

Raw chart and full-history price indicators begin at the captured split on Sep 15, 2022; bars on opposite sides are not compared.

Up next

filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$100,000
Trailing 12 months
Net income (TTM)
−$14.62M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
-16,428.0%
Trailing 12 months
P / E (TTM)
Trailing earnings
FCF yield
-72.0%
TTM · current market cap
Return on invested capital
Trailing 12 months
Net cash
Latest balance sheet
Dividend yield
Trailing 12 months
Shares change YoY
+5.8%
Year over year · more shares
Price change (1Y)
-14.7%
Trailing year
Short interest
1.0%
Latest settlement · 1.1 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Neutral Sentiment Bearish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 16.5 · calm Equity put/call 0.67
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −39%
below
Price vs 50-day avg −5%
below
RSI (14) 60
neutral
MACD trend Positive
52-week position 22%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Neutral
1-month return +57%
trailing
6-month return −62%
trailing
YTD return +2%
this year
Relative strength −77%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow Distributing
-9% holders QoQ · +3 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.00% of float · ▲ +59.5% MoM · 1.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
32 holders — mid 3-yr range
Squeeze score 59
elevated · 0–100
Fundamentals
Strong
Revenue growth +57%
Y/Y
Gross margin 5%
contracting
EPS growth +20%
Y/Y
Free cash flow $-16.0M
Balance sheet $29.2M
net cash
Quant / Vol
risk profile
Very High
Volatility 127%
annualized · 1-yr
Max drawdown −80%
past year
ATR 12.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 5 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−39% Bearish
Price vs 50-day avg
−5% Neutral
RSI (14)
60 Neutral
MACD trend
Positive Bullish
52-week position
22% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow Distributing
-9% holders QoQ · +3 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
1.00% of float · ▲ +59.5% MoM · 1.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
32 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $2 · 22% Range high $5
vs 200-day avg -39% vs 50-day avg -5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
LSTA
Lisata Therapeutics, Inc.
this stock
$17.12M +2.2% +56.9% 1.0%
VRTX
Vertex Pharmaceuticals Inc / Ma
$132.08B +14.9% +46.2% 30.4 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
$83.15B +4.6% +20.8% 20.0 2.3%
ARGX
Argenx SE
$62.33B +19.2% 1.9%
CSLLY
Csl Ltd
$58.10B 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
32
% held
12.1%
Net QoQ
+31.8K sh
Top holder
VANGUARD CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
10
View
Short & Settlement
Short Interest Rising
Shares short
89.9K
Days to cover
1.1d
Change
+33.5K sh
View
Short Volume
Short vol %
16%
As of
Sep 9, 2026
Short Total
View
Fails to Deliver
FTD shares
1.2K
Value
$1.4K
As of
Jul 29, 2026
View
Off-Exchange
Off-exchange %
62.0%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$170.0K
Net income (FY)
$-16.6M
EPS diluted
$-1.91
View
Filings
SEC Filings
Latest
10-Q
Filed
Aug 6, 2026
This year
17
View
Exempt Offerings
Offering
$25.0M
Filed
Feb 1, 2021
View
Earnings & Events
Earnings Calls
Last call
Nov 6, 2025
View

Performance

Raw-price comparisons begin at the captured split on Sep 15, 2022; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
LSTA +21.0% +57.0% -62.1% +27.5% +2.2%
SPY +0.1% -1.1% +15.3% -0.6% +11.8%
vs SPY +20.9% +58.1% -77.4% +28.1% -9.7%
Key facts CIK 320017 CUSIP 128058302 13F (30d) 22 filings 22 filers Visit website Investor relations